Homozygous TAF8 mutation in a patient with intellectual disability results in undetectable TAF8 protein, but preserved RNA polymerase II transcription by El-Saafin, Farrah et al.
                          El-Saafin, F., Curry, C., Ye, T., Garnier, J. M., Kolb-Cheynel, I., Stierle, M.,
... Tora, L. (2018). Homozygous TAF8 mutation in a patient with intellectual
disability results in undetectable TAF8 protein, but preserved RNA
polymerase II transcription. Human Molecular Genetics, 27(12), 2171-2186.
https://doi.org/10.1093/hmg/ddy126
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC
Link to published version (if available):
10.1093/hmg/ddy126
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Oxford Academic
at  https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg/ddy126/4966921. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
O R I G I N A L A R T I C L E
Homozygous TAF8mutation in a patient with
intellectual disability results in undetectable TAF8
protein, but preserved RNA polymerase II transcription
Farrah El-Saafin1,2,3,4, Cynthia Curry5,6, Tao Ye1,2,3,4, Jean-Marie Garnier1,2,3,4,
Isabelle Kolb-Cheynel1,2,3,4, Matthieu Stierle1,2,3,4, Natalie L. Downer8,
Mathew P. Dixon8, Luc Negroni1,2,3,4, Imre Berger7, Tim Thomas8,9,
Anne K. Voss8,9, William Dobyns10,11, Didier Devys1,2,3,4,* and
Laszlo Tora1,2,3,4,*
1Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, 67404 Illkirch, France, 2Centre National de la
Recherche Scientifique, UMR7104, 67404 Illkirch, France, 3Institut National de la Sante´ et de la Recherche
Me´dicale, U1258, 67404 Illkirch, France, 4Universite´ de Strasbourg, 67404 Illkirch, France, 5University of
California, San Francisco, San Francisco, CA, USA, 6Genetic Medicine, University Pediatric Specialists, Fresno,
CA 93701, USA, 7School of Biochemistry and Bristol Research Centre for Synthetic Biology BrisSynBio,
University of Bristol, Bristol BS8 1TD, UK, 8Walter and Eliza Hall Institute of Medical Research, Parkville, VIC
3052, Australia, 9Department of Medical Biology, University of Melbourne, Parkville, VIC 3052, Australia,
10Departments of Pediatrics and Neurology, University of Washington, Seattle, WA 98101, USA and 11Center for
Integrative Brain Research, Seattle Children’s Research Institute, Seattle, WA 98101, USA
*Correspondence to be addressed. Tel: þ33 388653442; Fax: þ33 388653201; Email: devys@igbmc.fr (D.D.); Tel: þ33 388653444; Fax: þ33 38865320;
Email: laszlo@igbmc.fr (L.T.)
Abstract
The human general transcription factor TFIID is composed of the TATA-binding protein (TBP) and 13 TBP-associated factors
(TAFs). In eukaryotic cells, TFIID is thought to nucleate RNA polymerase II (Pol II) preinitiation complex formation on all pro-
tein coding gene promoters and thus, be crucial for Pol II transcription. In a child with intellectual disability, mild microceph-
aly, corpus callosum agenesis and poor growth, we identified a homozygous splice-site mutation in TAF8 (NM_138572.2:
c.781–1G>A). Our data indicate that the patient’s mutation generates a frame shift and an unstable TAF8 mutant protein
with an unrelated C-terminus. The mutant TAF8 protein could not be detected in extracts from the patient’s fibroblasts, indi-
cating a loss of TAF8 function and that the mutation is most likely causative. Moreover, our immunoprecipitation and proteo-
mic analyses show that in patient cells only partial TAF complexes exist and that the formation of the canonical TFIID is im-
paired. In contrast, loss of TAF8 in mouse embryonic stem cells and blastocysts leads to cell death and to a global decrease in
Pol II transcription. Astonishingly however, in human TAF8 patient cells, we could not detect any cellular phenotype,
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significant changes in genome-wide Pol II occupancy and pre-mRNA transcription. Thus, the disorganization of the essential
holo-TFIID complex did not affect global Pol II transcription in the patient’s fibroblasts. Our observations further suggest that
partial TAF complexes, and/or an altered TFIID containing a mutated TAF8, could support human development and thus, the
absence of holo-TFIID is less deleterious for transcription than originally predicted.
Introduction
In order for a gene to be transcribed, a transcriptional preinitia-
tion complex (PIC) needs to assemble at its promoter. The first
complex to bind the promoter is the general transcription fac-
tor, TFIID, consisting of the TATA-binding protein (TBP) and 13
different TBP-associated factors (TAFs) (1,2). Following TFIID
binding, other general transcription factors (TFIIA, TFIIB, TFIIE,
TFIIF and TFIIH) and RNA polymerase II (Pol II) are recruited to
the promoter (3). Nine of the TAFs contain a histone fold do-
main (HFD), and form five histone fold pairs. TAF8 is an HFD-
containing TAF which forms a histone fold pair with TAF10 in
TFIID (4,5). Biochemical studies revealed that the TFIID complex
is assembled in a step-wise manner, first forming a stable core
complex consisting of TAF5, TAF6-TAF9 and TAF4-TAF12. This
core is then bound by TAF2 associated with the TAF8-TAF10
heterodimer, forming the 8TAF complex. Next, TBP and the
remaining TAFs join the 8TAF complex, to form holo-TFIID (6,7).
Studies performed in yeast show comprehensively that
TFIID is recruited to almost all promoters and is required for the
transcription of all Pol II transcribed genes (8). In agreement, in-
dividual yeast TAFs are essential for viability. Similarly, germ
line knock-out of several TFIID subunits in mouse (Taf7, Taf8,
Taf10 and Tbp) results in early embryonic lethality around E4.0
(9–12), suggesting that these mammalian TFIID subunits are ab-
solutely essential for blastocyst viability and early development.
Furthermore, conditional deletion of Taf4 or Taf10, in embryonic
keratinocytes (13,14), deletion of Taf10 in embryonic liver (15), or
ablation of Taf7 in CD4–CD8– thymocytes (9) compromises the
viability of the mutant cells, suggesting that these TFIID subu-
nits play an essential role in transcription in these cell types.
Curiously, however, deletion of Taf10 in postnatal liver
resulted in a less dramatic phenotype compared with the lack
of Taf10 during embryogenesis, with mild effect on transcription
of liver genes (15). Similarly, in adult mouse keratinocytes, dele-
tion of Taf10 had no effect on epidermal function and no appar-
ent effect on transcription (13). Also, mouse CD4þCD8þ T-cells
lacking Taf7 appear to be viable with no apparent effect on tran-
scription (9). Together these animal studies demonstrate that
many cell types absolutely require the canonical TFIID complex
for transcription and survival; however, certain cell types are
seemingly unaffected by loss of TFIID subunits. How and why
these transcription regulatory differences occur amongst differ-
ent cell types of embryonic and/or adult origin is not
understood.
Several different human TFIID subunit coding genes (TBP,
MIM: 600075; TAF1, MIM: 313650; TAF2, MIM: 604912; TAF6, MIM:
602955; and TAF13, MIM: 600774) have been implicated in hu-
man diseases including many with neurological outcomes and
intellectual disability (16–28). A polyglutamine expansion in TBP
has a well-characterized gain of function effect resulting in a
neurodegenerative disorder, spinocerebellar ataxia-17
(17,19,22,24,26,27,28). In contrast, most of the other reported
mutations in genes encoding TFIID subunits are recessive mis-
sense mutations in different TAFs found in patients with intel-
lectual disability and various degree of developmental delay
and microcephaly (16,18,21,23,25,28). The outcome of these
mutations on TFIID structure and function was not assessed in
detail, but it can be expected that they cause, to a variable de-
gree, a partial loss of function of the corresponding protein and
potentially of TFIID.
In the present study, we identified a homozygous splice site
mutation in TAF8 in a patient presenting with intellectual dis-
ability, developmental delay and mild microcephaly. The muta-
tion resulted in a frame shift changing the C-terminus of TAF8.
The mutant TAF8 protein was undetectable by either western
blot analysis or mass spectrometry in cell extracts as well as in
TAF-containing complexes purified from the patient fibroblasts.
We show that TFIID assembly is impaired in the patient fibro-
blasts, but astonishingly, there was no significant reduction of
the genome-wide RNA Pol II occupancy, elongation rates and
pre-mRNA synthesis.
Results
Intellectually disabled child identified with a TAF8:
c.781–1G>Amutation
A girl, first seen at 15 months of age, presented with severe
global developmental delay and intellectual disability. She was
born to non-consanguineous 15- and 17-year-old Hispanic
parents after an uncomplicated term pregnancy. Growth
parameters have been at –4–5 SD for height and weight and –2
SD for head circumference. Her development has been severely
delayed with smiling by 3–4 months and rolling at a year. At age
4.5 years she cannot sit or speak. She has developed progressive
spasticity and equinovarus foot deformities. However, she does
not have seizures and her general health is reasonably good
without intercurrent hospitalizations. Her craniofacial findings
include brachycephaly, a mildly short forehead, a tented mouth,
mild left sided ptosis and a long philtrum (Fig. 1A). Her hands
and feet are unremarkable except for the progressive deformi-
ties of her feet.
Extensive genetic evaluation revealed a normal chromo-
somal SNP microarray without excessive homozygosity, normal
metabolic studies including glycosylated transferrin, lactate,
acylcarnitine profile, very long chain fatty acids and urine or-
ganic and plasma amino acids. Two MRI’s have revealed mild
microcephaly, reduced myelination, a small cerebellar vermis
and partial absence of the corpus callosum (Fig. 1B).
Exome sequencing revealed a homozygous splice site vari-
ant in TAF8 [NC_000006.12: g.42077099G>A (NM_138572.2:
c.781–1G>A)] (Fig. 1C), whereas no other mutation or variant in
genes possibly associated with the phenotype could be identi-
fied. Both parents were found to be heterozygous for the same
variant. This change was observed in the Genome Aggregation
Database (gnomAD) in the heterozygous state in ten individu-
als, including five of Hispanic origin, out of 277264 alleles.
TAF8: c.781–1G>A variant generates a cryptic splice site
resulting in a frame shift in the TAF8mRNA
As the TAF8: c.781–1G>A mutation in the 30 end of intron 7 of
the TAF8 gene occurred in a predicted splice acceptor site
2 | Human Molecular Genetics, 2018, Vol. 0, No. 0
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy126/4966921
by University of Bristol Library user
on 04 June 2018
(Fig. 1C), we analyzed the consequences of this mutation on
TAF8 mRNA and protein. To determine the outcome of the mu-
tation, reverse transcriptase-polymerase chain reaction (RT-
PCR) analyses were performed on RNA extracted from control
and patient fibroblasts using a combination of primers
(Supplementary Material, Table S1). These analyses excluded
skipping of exon 8 or intron 7 retention (Supplementary
Material, Fig. S1A and B). Sequencing of a cDNA fragment gener-
ated by RT-PCR using primers annealing in exons 7 and
8 revealed that a cryptic splice acceptor site, one base pair
downstream of the original one, was utilized instead of the orig-
inal splice acceptor site, in the patient fibroblasts. As a result,
exon 8 was missing the first G nucleotide (Fig. 1C and D), caus-
ing a frame shift. Identical results were observed when the sam-
ples were treated with emetine, a non-sense mediated decay
inhibitor (29), confirming that this cryptic acceptor site is exclu-
sively used in the mutant fibroblasts. Quantitative PCR (qPCR)
was carried out on mutant and control cDNA, using primers
amplifying the junction between exon 2 and 3, which revealed
that the abundance of the mutant TAF8 mRNA was mildly re-
duced by about 30% in the patient cells. This mild reduction is
likely caused by non-sense mediated decay, because treatment
with emetine restored normal levels of TAF8 mRNA (Fig. 1E).
The TAF8: c.781–1G>A gene encodes a highly unstable
protein lacking the C-terminal nuclear localization
signal
The amino acid sequence produced from the mutant TAF8 cDNA
was predicted using an in silico translation tool. Loss of the first G
nucleotide in exon 8, results in a frame shift, affecting the final 50
amino acids of the ‘wild-type’ (WT) TAF8 protein, creating a dif-
ferent C-terminus in the mutant TAF8 protein and a premature
stop codon encoded in the 8th exon (Fig. 2A). In the WT TAF8 se-
quence, the stop codon is in the last 9th exon (Fig. 1C). The region
Figure 1. Developmentally delayed child identified with c.781–1G>A mutation in TAF8 gene. (A) Photographs of patient at 3 years of age (top) and 4 years of age (bot-
tom). (B) Brain MRI acquired at 2 years and 7 months of age shows (sagittal on top and two transversal levels on bottom) mildly prominent extra-axial spaces, diffuse
thinning of white matter with delayed myelinization, borderline enlarged lateral ventricles, short corpus callosum with narrow posterior body and absent splenium,
normal brainstem, borderline small cerebellar vermis, and mildly small posterior fossa size. (C) (Top) Patient and control genomic sequences at the intron 7–exon
8 boundary of interest. Asterisk highlights the G>A splice site mutation (in red). Capital letters show exon 8 coding nucleotides. (Bottom) Schematic representation of
the TAF8 gene (not to scale) with the position of the mutation indicated by the red asterisk. (D) Sequencing chromatogram highlighting the G nucleotide missing from
the beginning of exon 8 in the patient cDNA. (E) RT-qPCR performed with primer annealing to the boundaries between exons 2 and 3, showing abundance of TAF8
mRNA in control and patient cells treated with and without emetine. Error bars represent SEM of three technical replicates. ***P<0.001.
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encompassing the TAF8 HFD, which is required for its pairing
with TAF10, is upstream of the frame-shift and is therefore unaf-
fected in the mutant TAF8 protein. The C-terminal region of the
WT TAF8 contains a nuclear localization signal (NLS) (30), which
is lost in the predicted mutant TAF8 protein (Fig. 2A). WT TAF8
protein has a predicted molecular weight of 34.3 kDa, but
migrates around the 43 kDa position (5). To detect the endoge-
nous mutant TAF8 protein, whole cell extracts (WCEs) were pre-
pared from control and mutant fibroblasts using two different
extraction methods (see Materials and Methods) and were sub-
jected to western blot analysis with two different polyclonal anti-
TAF8 antibodies (pAb 3477 and 3478), which were generated
against the entire TAF8 protein. Unexpectedly, mutant TAF8 pro-
tein was not detected in patient fibroblasts (Fig. 2B and C lanes 2
and 3), irrespective of mutant TAF8 mRNA levels (Fig. 1E). To ex-
clude the possibility that the anti-TAF8 pAbs are unable to detect
the mutant TAF8 protein because of its unique carboxyl terminus,
we generated recombinant baculoviruses expressing the mutant
TAF8 protein fused to an N-terminal FLAG tag. The anti-TAF8
pAb readily detected the mutant FLAG-TAF8 fusion protein when
highly over-expressed in Sf9 insect cells (Fig. 3A).
These results suggest that the mutant TAF8 protein, as com-
pared with WT, may be less stable and prone to degradation in
patient cells. To verify the stability of the mutant TAF8 in a dif-
ferent cellular system, first insect Sf9 cells were infected with
baculoviruses expressing either FLAG-tagged WT, or mutant
TAF8. When identical total protein amounts from both WT and
mutant TAF8 expressing cells were analyzed by western blot,
the mutant TAF8 protein was hardly detectable, although high
levels of WT TAF8 were detected (Fig. 3B, compare lanes 3 and 4
with 5 and 6). Importantly, however, both WT and mutant TAF8
expressing Sf9 cells contained comparable amounts of TAF8
mRNAs (Fig. 3C), suggesting that the altered final 50 C-terminal
amino acids lead to instability of the mutant TAF8 protein.
Secondly, to determine whether the mutant TAF8 mRNA is
translated into protein at a similar rate as the WT TAF8 mRNA,
we generated a single cassette system which co-expresses
FLAG-tagged WT, or mutated TAF8 proteins, together with
FLAG-green fluorescent protein (GFP), separated by the P2A
‘self-cleaving’ 22 amino acid peptide. Importantly, the P2A se-
quence mediates ribosome-skipping, enabling the generation of
equal amounts of two separate peptide products from a single
mRNA (31,32). When the WT FLAG-TAF8 was expressed with
FLAG-GFP from the same cassette (Fig. 3D), using a baculovirus
expression system in insect cells, approximately equal amount
of the two proteins were detected (Fig. 3E, lane 3). However, in
good agreement with our earlier results, when the mutated
FLAG-TAF8 was expressed with FLAG-GFP from the same cas-
sette (Fig. 3D), the mutated FLAG-TAF8 was hardly detectable,
although the FLAG-GFP, produced from the same mRNA, was
readily detected (Fig. 3E, lane 4). These results unequivocally
demonstrate that the mutated TAF8, containing the unrelated
50 C-terminal amino acids, is intrinsically unstable.
Degradation of the mutant TAF8 protein could be mediated
by the proteasome. In order to test this hypothesis, patient and
control fibroblasts were treated with the proteasome inhibitor
MG132 for 12 or 18 h, and then western blot analysis was con-
ducted. In untreated samples, the WT TAF8 protein was readily
detected, although the mutant TAF8 protein was not. However,
in the patient fibroblasts treated with MG132, a protein, smaller
than the WT TAF8 protein was detected, likely corresponding to
the mutant TAF8 protein (Fig. 2C). These results suggest that
degradation of the mutant TAF8 protein is likely carried out, at
least partially, by the proteasome.
Together these results show that the TAF8: c.781–1G>A mu-
tation generates a protein with a unique C-terminus that is
prone to degradation, causing an apparently complete loss of
function of TAF8, further indicating that TAF8: c.781–1G>A,
p.Glu261Argfs*38 is most likely the causative mutation in this
patient.
Ablation of mouse TAF8 protein in embryonic stem cells
results in cell death caused by transcriptional defects
The human patient fibroblasts lacking any detectable TAF8 pro-
tein were apparently healthy. Thus, we decided to investigate
mouse cells in which TAF8 protein elimination can be induced
by Taf8 knock-out. Mouse blastocysts lacking Taf8 die very early
during development, at around embryonic day 4.0 (E4.0), be-
cause of apoptosis in the inner cell mass (ICM) (12). To be able to
monitor the direct consequences of inducible TAF8 protein abla-
tion, we used Taf8lox/lox: Rosa26-CreERT2 mouse embryonic
stem cells (mESCs), in which Taf8 deletion can be induced by
the addition of 4-hydroxy Tamoxifen (4-OH) (Supplementary
Material, Fig. S2A). Cells were seeded at a density of 8 105 cells
per well and every second day, live and dead cells were counted,
then 8 105 cells were reseeded. After 8 days of treatment, there
was a massive reduction in the number of live cells, and an in-
crease in dead cells, in the Taf8lox/lox: Rosa26-CreERT2 cultures
treated with 4-OH tamoxifen, as compared with control cultures
(Fig. 4A–C). The cell death observed in the tamoxifen treated
Taf8lox/lox: Rosa26-CreERT2 mESCs correlated with a gradual in-
crease in the deletion of the Taf8 allele (Supplementary
Material, Fig. S2B) and a gradual depletion of TAF8 protein, with
no TAF8 protein detected after day 6 (Fig. 4D).
Next, we wanted to determine if TAF8 depletion causes
global transcriptional defects. As steady-state mRNA levels can
be buffered by modulation of mRNA decay, especially in situa-
tions where Pol II transcription is globally impaired [(8,33,34)
and references therein], we measured newly synthesized pre-
mRNA using primers that amplify an intron–exon boundary in
unspliced pre-mRNA. Pre-mRNA transcript abundance was nor-
malized to the RNA Pol I transcribed 45S pre-rRNA, which is not
affected by loss of Taf8. For all tested genes, the abundance of
pre-mRNAs was reduced by about 2-fold upon TAF8 depletion,
suggesting a global defect in Pol II transcription in the absence
of TAF8. Together, these experiments show that mESCs die in
the absence of mouse TAF8, similarly to the in vivo Taf8–/– blas-
tocyst phenotype reported by Voss et al. [12], and our prelimi-
nary transcriptional analysis suggests that a global decrease in
PIC formation correlates with cell death.
The lack of detectable human TAF8 protein dramatically
alters the assembly of the TFIID complex in patient
fibroblasts
As the patient fibroblasts did not present any obvious phono-
type when compared with control fibroblasts, we next assessed
if TFIID integrity was affected in the cells harboring the TAF8:
c.781–1G>A mutation. To this end, WCEs were prepared from
control and TAF8 mutant fibroblasts and subjected to immuno-
precipitations (IPs) using anti-TAF7, anti-TBP or anti-TAF10
antibodies to capture the TAF7-, TBP- or TAF10-containing com-
plexes. The abundance of the TFIID subunits tested was similar
in the WCEs from control and patient cells (Fig. 5A–C, lanes 1
and 2). Likewise, the amount of bait protein captured by the cor-
responding antibody was similar (Fig. 5A–C, lanes 3 and 4).
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However, in complexes purified using either anti-TAF7, anti-
TBP or anti-TAF10 antibodies, the levels of several of the tested
TFIID subunits was markedly reduced in the patient fibroblasts
when compared with intact TFIID complexes purified from con-
trol cells (Fig. 5A–C, compare lanes 3 and 4).
To detect potential very low levels of mutant TAF8 protein
and additional TFIID subunits with a higher sensitivity and in a
more quantitative way, anti-TAF10 immunopurified complexes
were analyzed by matrix assisted laser desorption ionisation-
time of flight mass spectrometry. To be able to compare the
composition of complexes purified from control and Taf8 mu-
tant cells, normalized spectral abundance factor (NSAF) values
were calculated (35). Although all the known TFIID subunits
were identified by mass spectrometry analysis of TAF10-
containing complexes isolated from control fibroblasts, we did
not detect any TAF8 peptides from the patient cells. We also did
not detect TAF1, TAF3, TAF11, TAF13 and TBP, which are sup-
posed to be present in a functional module of TFIID, which does
not contain the TAF8/10 histone fold pair (6) (Fig. 5D,
Supplementary Material, Table S2). Moreover, the bait-
normalized anti-TAF10 immunopurification performed on pa-
tient cells identified eight TFIID subunits (TAF2, TAF4, TAF5,
TAF6, TAF7, TAF9/9b and TAF12) with significantly less peptide
counts than detected in the control sample (Fig. 5D). It should
Figure 2. The TAF8: c.781–1G>A mutant protein lacks an NLS and is degraded by the proteasome. (A) Amino acid sequence of WT TAF8 protein aligned to the in silico
predicated amino acid sequence generated by the TAF8: c.781-1G>A mutation, which possesses a unique carboxy-terminus (depicted in red), and lacks an NLS
(depicted in grey highlight in the WT sequence). Histone fold domain in the WT sequence is highlighted in blue. (B) Two different protein WCE (WCE1 and WCE2) prepa-
rations (see Materials and Methods) were analyzed by western blot. Blots were probed with two different polyclonal anti-TAF8 antibodies (affinity purified pAb 3478
and crude pAb 3477 serum) targeting the entire TAF8 protein, as indicated. (C) Patient and control fibroblasts were treated with MG132 for 12 or 18 h, WCEs were pre-
pared and probed with an anti-TAF8 antibody (affinity purified pAb 3477). The presence of a smaller protein, likely corresponding to the mutant TAF8 protein was
detected in the presence of MG132.
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be noted that the overall peptide counts were rather low, likely
owing to the overall low level of TFIID subunits in fibroblasts
relative to other cell types (Supplementary Material, Fig. S3).
Therefore, we cannot exclude the possibility that low levels of
mutant TAF8 protein are present in the TFIID complexes puri-
fied with anti-TAF10 antibodies, but the levels were below the
detection limit.
Taken together, these results indicate that in the fibroblasts
harboring the TAF8: c.781–1G>A mutation, the lack of detect-
able mutant TAF8 results in TFIID disassembly to partial TAF-
containing complexes, in spite of the fact that the abundance of
TFIID subunits (with the exception of TAF8 protein) in the input
extracts seem to be unaffected (Fig. 5A–C). Because of the crucial
role of TFIID in transcription initiation and during early
embryonic mouse development, these observations together of-
fer a likely causative explanation for the homozygous TAF8:
c.781–1G>A mutation in the patient phenotype.
A defective TFIID complex does not cause a global
reduction of the genome-wide RNA Pol II occupancy and
elongation rates
Because TFIID was disassembled in fibroblasts harboring the TAF8:
c.781–1G>A mutation (Fig. 5), we set out to verify whether the global
recruitment of RNA polymerase II to active promoters may also be
compromised. To test this possibility, control and patient fibroblasts
were subjected to chromatin immunoprecipitation (ChIP) coupled to
Figure 3. Exogenously expressed TAF8 mutant protein is unstable. (A) WCEs from insect Sf9 cells were prepared with either no infection, or with infection of a recombi-
nant baculovirus encoding the TAF8: c.781-1G>A mutant protein fused to an FLAG tag and western blot assays were carried out using purified anti-TAF8 pAb 3478.
(B) Western blot analyses of WCEs generated from Sf9 cells either with no infection, infection with recombinant baculovirus encoding FLAG tagged WT TAF8, or FLAG-
tagged mutant TAF8 (FL-TAF8 MUT) protein, probed either with anti-FLAG antibody (upper blot), or affinity purified anti-TAF8 pAb 3478 (middle blot). Each lane repre-
sents an independent infection. (C) RT-qPCR performed with primers annealing to the boundary between exons 2 and 3 of TAF8 mRNA normalized to Sf9 housekeeping
genes 28S, GAPDH and L35, performed on cDNA generated from Sf9 cells with either no infection, or infected with recombinant baculovirus encoding WT TAF8 protein
or TAF8: c.781-1G>A mutant protein. All values were normalized to the average of the WT TAF8 infection. Error bars represent SEM of three technical replicates. See
Supplementary Material, Table S1 for primer sequences. (D) Schematic representations of the cassettes expressing a single mRNA encoding either WT FLAG-TAF8 or
mutant FLAG-TAF8 together with FLAG-GFP separated by the self-cleavage P2A sequence. (E) Western blot analyses of WCEs generated from Sf9 cells either with no in-
fection, infection with recombinant baculovirus encoding FLAG tagged WT TAF8-P2A-FL-GFP, or FLAG-tagged mutant TAF8 (FL-TAF8 MUT- P2A-FL-GFP) protein, probed
either with anti-FLAG antibody (upper blot), anti-GFP (lower blot). In A and B, for Ponceau staining 5 the amount of protein was loaded as compared with the western
blots. In A, B and E, the molecular weight (MW) markers are indicated in kDa.
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high throughput sequencing (ChIP-seq), using a mouse monoclonal
antibody recognizing the C-terminal domain (CTD) of the largest sub-
unit of Pol II (RPB1, hereafter called anti-Pol II ChIP-seq). Anticipating
that subtle difference may be present between the Pol II occupancies
at promoters in the control and patient fibroblasts, which may be
difficult to quantify, we added a consistent trace amount of
Drosophila chromatin to the human fibroblast chromatin at the be-
ginning of the ChIP procedure. As the antibody used in this experi-
ment recognizes the CTD of both human and Drosophila RPB1, the
two distinct human chromatin preparations were normalized to the
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Figure 4. mESCs induced to delete Taf8 undergo cell death potentially as a result of transcriptional defects. (A) Representative images of Taf8lox/lox or Taf8lox/lox-Rosa26-
CreERT2 mESCs after 8 days of culture with or without 0.5 mM 4-hydroxy tamoxifen treatment (4-OH). See also Supplementary Material, Figure S2A. (B) Curve showing
the cumulative number of viable mESCs over the course of the treatment, cell counts were plotted taking into account the dilution factor at each passage. (C) Cell death
was measured by trypan blue exclusion over the course of the treatment (as indicated). (D) Western blot analyses to detect TAF8 protein with the affinity purified 3478
pAb during several days (d) of 4-hydroxy tamoxifen (4-OH) treatment. Equal loading was measured by using an anti-c-tubulin antibody. MW markers are indicated in
kDa. (E) RT-qPCR of randomly selected, highly expressed genes, measuring newly synthesized mRNA relative to Pol I transcribed pre-rRNA 45S. The list of the primers
is indicated in Supplementary Material, Table S1. For all experiments three biological replicates were carried out per genotype. Error bars represent SEM.
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Drosophila ‘spike-in.’ Surprisingly, Pol II occupancy at selected repre-
sentative Pol II transcribed genes (Fig. 6A), and genome-wide, ana-
lyzed by either K-means clustering (Fig. 6B) or by metagene plots
(Fig. 6C), did not change significantly when compared with control
cells. Selecting a few representative Pol II-bound promoters (Fig. 6A),
the ChIP-seq results were validated by ChIP-qPCR. This validation
further confirmed the surprising observation that in patient fibro-
blasts the Pol II occupancy at the selected promoters was not signifi-
cantly altered (Supplementary Material, Fig. S4A). Thus, in spite of
the complete disorganization of holo-TFIID, Pol II occupancy across
all transcribed genes did not change dramatically in patient fibro-
blasts harboring the TAF8: c.781–1G>A mutation (Fig. 6A–C).
Next, we wanted to determine if Pol II pausing at promoters
and/or elongation rates in gene bodies was altered in the pa-
tient cells compared with control. To this end we measured the
Pol II travelling ratio, which is defined as the ratio of the Pol II
occupancy signal at the promoter [from –100 to þ300 bp around
the transcription start site (TSS)] relative to the Pol II signal in
the gene body (from þ300 to þ2 kb) (36,37). Because the Pol II
ChIP-seq signal in the gene body can be close to background, we
clustered the genes on the basis of Pol II signal in their gene
body (Supplementary Material, Fig. S4B), and calculated Pol II
travelling ratio [(37) and see Materials and Methods] for two
gene clusters having significant gene body signal. In the first
cluster, consisting of 580 genes, the Pol II promoter pausing and
gene body signals as well as Pol II travelling ratios were similar
between patient and control fibroblasts (Fig. 6D and
Supplementary Material, Fig. S4C). In cluster 2, consisting of
1102 genes (Supplementary Material, Fig. S4B), Pol II promoter
pausing was slightly decreased and the Pol II signal in the gene
body was somewhat higher in patient’s fibroblasts compared
with control fibroblasts (Fig. 5E). As a consequence, the Pol II
travelling ratio was shifted to the left in patient fibroblasts com-
pared with control (Supplementary Material, Fig. S4D), suggest-
ing that in cluster 2 genes, Pol II was slightly redistributed from
promoters to genes bodies in the mutant fibroblasts.
Figure 5. TFIID assembly is defective in fibroblasts harboring the TAF8: c.781–1G>A mutation. (A–C) Coimmunoprecipitation performed on WCEs prepared from con-
trol, or TAF8: c.781-1G>A patient fibroblasts, using either anti-TAF7 and anti-GST (negative control) antibodies (A) or anti-TBP and anti-GST (B) or anti-TAF10 and anti-
GST (C). Input extracts or immunopurified complexes were separated by SDS-PAGE and western blot analyses were carried out by probing the blots with antibodies
against the indicated TFIID subunits. The anti-GST antibody heavy (IgG H) and light chains (IgG L) are indicated. Ponceau-stained membranes in A–C show equal load-
ing. In A–C the MW markers are indicated in kDa. (D) Mass spectroscopy performed on proteins co-IP-ed with anti-TAF10 antibody, normalized to TAF10 bait protein.
Relative NSAFbait was calculated as described previously (52). Error bars represent SEM of two technical replicates. See Supplementary Material, Table S2 for raw mass
spectrometry peptide counts.
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Figure 6. Genome wide RNA polymerase II occupancy and transcription is not significantly effected in fibroblasts harboring the TAF8: c.781–1G>A mutation. (A) UCSC
genome browser snapshots of randomly selected representative genes showing Pol II occupancy in control fibroblasts (HFF-1, purple) and TAF8: c.781-1G>A patient
fibroblasts (red). Arrows at TSSs show the direction of transcription. (B) Heatmap of anti-Pol II ChIP-seq generated by K-means clustering in a window showing TSS to
transcription termination site (TTS) of all genes in control and patient fibroblasts. (C) Metagene plots of all expressed Pol II transcribed genes, generated from spike-in
normalized anti-Pol II ChIP-seq, on control fibroblasts and TAF8 mutant fibroblasts. Average Pol II profiles were calculated for every expressed refseq gene from –5 kb
region upstream of every TSS, including the gene bodies (GBs), until þ5 kb downstream from the TTS. The Y-axis shows mean tag/50 bp densities. (D and E) On the basis
of the clustering of Pol II occupancy in the gene bodies (Supplementary Material, Fig. S3B) Cluster 1 (D), containing 580 genes (Supplementary Material, Table S3), and
Cluster 2 (E), containing 1102 genes (Supplementary Material, Table S4), profiles from –2 to þ2 kb relative to TSS are shown. From these profiles, the corresponding Pol II
traveling ratios were calculated and are depicted in the Supplementary Material, Figure S3C and D. In C–E, control graphs are in blue and patient graphs in pink. (F) RT-
qPCR of newly transcribed mRNA in control fibroblasts and TAF8: c.781-1G>A patient fibroblasts of 11 representative genes normalized to the Pol I transcribed 45S pre-
rRNA. Primers for each gene amplify fragments either only in introns or overlapping intron–exon boundaries from the indicated pre-mRNA. See Supplementary
Material, Table S1 for primer sequences.
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Loss of TAF8 and holo-TFIID complex do not alter mRNA
synthesis from selected genes
The lack of obvious changes in the overall distribution of RNA
Pol II despite the undetectable mutant TAF8 protein and
holo-TFIID (Figs 5 and 6), suggested that transcription may not
be dramatically affected in the patient fibroblasts. To verify
this hypothesis, the level of pre-mRNA transcription of ran-
domly selected genes was measured by RT-qPCR. Because
steady-state levels of mRNA, determined by assessing total
mRNA abundance, are modulated by mRNA decay rates
[(8,33,34) and references therein], we measured the abundance
of newly synthesized unspliced pre-mRNA relative to the
abundance of the newly synthesized RNA polymerase I tran-
scribed 45S pre-rRNA (Fig. 6F). Consistent with the lack of sig-
nificant Pol II occupancy changes (Fig. 6A–E), we found that the
level of transcription of all the tested genes was not affected in
the patient fibroblasts as compared with two control fibroblast
cell lines (Fig. 6F). In addition, we tested the abundance of
some Pol II transcribed histone mRNAs, snRNA and snoRNAs
in patient fibroblasts compared with control fibroblasts
(Supplementary Material, Fig. S4E) and found no significant
changes. Together, these results indicate that in the fibroblasts
harboring the TAF8: c.781–1G>A mutation, on average,
genome-wide RNA pol II occupancy, Pol II elongation rates and
pre-mRNA transcription are not dramatically impaired com-
pared with control fibroblasts.
Discussion
In this study, we identified a patient with severe intellectual
disability and developmental delay, who inherited a homozy-
gous splice site mutation in TAF8 (c.781–1G>A), encoding a
subunit of the general transcription factor TFIID. In the patient
fibroblasts, TAF8 protein was undetectable by western blotting
and/or mass spectrometry analyses in WCEs as well as in
immunopurified TAF-containing complexes (Figs 2B and C and
5). The much lower levels of mutant TAF8 compared with WT
TAF8 protein in the different recombinant expression systems
used, clearly shows that the mutant protein is intrinsically un-
stable (Fig. 3). The identified mutation leads to a seemingly
complete loss of TAF8 function, and subsequent disassembly
of the TFIID complex. These observations are highly unex-
pected given the key role attributed to TFIID in transcription.
Indeed, in the mouse, germline deletion of Taf8 results in em-
bryonic lethality at E4.0, because of apoptosis of the pluripo-
tent ICM cells of the blastocyst (12). This early lethality
demonstrates that in the absence of TAF8 protein mouse blas-
tocysts cannot undergo gastrulation, organogenesis and fur-
ther embryonic development. Moreover, we also demonstrate
here that the inducible deletion of Taf8 in mESCs leads to cell
death and globally affects Pol II transcription (Fig. 4). Mouse
and human TAF8 proteins are 95.5% identical, and the TFIID
complex as a whole is highly conserved between mouse and
human. Although suffering from severe neurological deficits,
the child identified in this study is physically mostly healthy
and has developed well beyond the stage that one would antic-
ipate if this mutation resulted in complete elimination of the
mutated TAF8 protein in all cell types during the early stages
of development.
We speculate that the TAF8 (c.781–1G>A) mutation did not
cause a complete loss of TAF8 function during early embryo-
genesis and that residual levels of mutated TAF8 could have
been sufficient to maintain blastocyst survival and embryo
development. In support of this hypothesis, we observed that
mESCs with low residual levels of TAF8 protein can survive
and divide similarly to controls (see day 4 of 4-OH treatment in
Fig. 4B and D); however, when TAF8 protein is completely lost,
mESCs rapidly undergo massive apoptosis. Thus, in the pa-
tient cells, low residual TAF8 protein incorporated in limiting
amounts of holo-TFIID, and partial TAF-containing complexes
lacking TAF8 (Fig. 5) are sufficient to maintain Pol II transcrip-
tion (Fig. 7). Alternatively, in the patient the mutant TAF8 pro-
tein might have been present in higher quantities during
embryo development, and/or maybe are higher in different
cell types of the patient, to which we had no access. Indeed, it
has been recognized that proteins can have different stabilities
in different cell types (38,39), likely owing to the interaction
with different factors in the varying cellular environments.
Nonetheless, from the experiments carried out on the human
mutated TAF8 patient fibroblasts and by comparison with the
effect of a complete loss of TAF8 function in mice, we conclude
that the homozygous TAF8: c.781–1G>A mutation is the dis-
ease causing mutation.
In the patient fibroblasts described in this study, TAF8 pro-
tein is not detectable, and TFIID was disassembled. However, re-
cruitment of RNA polymerase II to promoters was not
significantly affected on a genome-wide scale. This result to-
gether with previous knowledge (9,13,15) suggests that the PIC
may exhibit more diversity than commonly thought and war-
rants further mechanistic investigations to determine the het-
erogeneity of PIC/TFIID function in different cell types.
Patient fibroblasts were used in this study, and although
they were useful for performing biochemical analyses, they fail
to explain the patient’s neurological phenotype. Our analyses
did not reveal a global defect in Pol II occupancy/transcription,
which could have been expected considering the extent of TAF8
depletion and TFIID disassembly. However, it is likely that Pol II
transcription is mildly impaired as a result of the TAF8 mutation
(see Fig. 7) leading to subtle changes in gene expression, which
may explain some aspects of the patient phenotype when oc-
curring during neurogenesis and brain development. This is
supported by our analyses suggesting putative minor changes
in Pol II elongation rates (see for example cluster 2 in Fig. 6 and
Supplementary Material, Fig. S4) which should be confirmed by
ChIP-seq using antibodies against phosphorylated serine 5 and
serine 2 Pol II CTD.
Although many links have been made between mutations in
genes encoding TFIID subunits and intellectual disabilities, the
outcome of the identified mutations appears different from that
of the TAF8: c.781–1G>A mutation identified here. This present
mutation appears to cause a nearly complete loss of TAF8 pro-
tein, whereas all other mutations identified in other TAF genes
were missense mutations expected to result in only partial loss
of function of the corresponding gene product. Homozygous
missense mutation and compound heterozygous mutations in
TAF2 were identified in two independent consanguineous fami-
lies presenting with autosomal recessive intellectual disability
associated with microcephaly and thin corpus callosum (18,40).
The impact of the TAF2 mutations on TFIID function was not ex-
plored experimentally, but TAF2 is known to interact with TAF8
(7), which could explain the apparent similarities between the
TAF2 and TAF8 patients. Recently, homozygous TAF13 missense
mutations, identified in two families with mild intellectual dis-
ability, growth retardation and microcephaly, were also sug-
gested to affect TFIID structure (25). Missense mutations in
TAF6 were also found associated with intellectual disability (16)
or an autism spectrum disorder (41). Because TAF6 forms part of
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the TFIID core (6), it is plausible that small alterations in its
structure could impact TFIID assembly. Of note, homozygous
missense mutations in TAF6 were found to be associated with a
Cornelia de Lange like syndrome and were reported to affect
TFIID assembly (42).
Hemizygous missense mutations in the X-linked TAF1 gene
were identified in male patients with a global developmental
delay, intellectual disability, facial dysmorphic features, micro-
cephaly and hypoplasia of the corpus callosum (23). The authors
predicted that the TAF1 mutations likely disrupted the TAF1–
TAF7 interaction, or the TAF1 bromodomain, likely affecting the
structure and/or function of TFIID (23). As noted earlier, the clin-
ical phenotypes observed in patients with mutations in several
TAFs partially overlap, in particular sharing common features
of variable intellectual disability and microcephaly. These simi-
larities suggest that a common molecular mechanism, namely
TFIID disruption, results in a secondary variable effect on Pol II
transcription in certain, but not all cell types.
In conclusion, our detailed TAF8 patient study, including bio-
chemical characterization of general transcription complexes
by mass spectrometry and genome-wide high throughput ChIP
analyses, together with previous less mechanistic reports of
patients with mutations in TAF genes, demonstrates that per-
turbed TFIID function is less deleterious for Pol II transcription
initiation than originally predicted. Additional studies using an-
imal model systems are needed to further delineate the exact
mechanism(s) responsible for the developmental, growth and
neurological abnormalities seen in individuals with TAF muta-
tions and to understand how cells can survive without holo-
TFIID.
Materials and Methods
Subject
Written parents’ consent was obtained for conducting the study
and showing MRIs and photographs of their affected child.
Exome sequencing
Exome sequencing performed by GeneDx revealed a homozy-
gous splice site variant in TAF8 [NC_000006.12: g.42077099G>A
(NM_138572.2: c.781–1G>A)] (Fig. 1C), whereas no other muta-
tion or variant in genes possibly associated with the pheno-
type could be identified. Both parents were found to be
heterozygous for the same variant. This change was observed
in the gnomAD in the heterozygous state in 10 individuals, in-
cluding 5 individuals of Hispanic origin. This variant was ob-
served once out of 12 065 alleles in the NHBLI exome
sequencing project.
Plasmids
The baculovirus expression vector for FLAG-tagged human TAF8
WT was PCR amplified from the pPBAC MultiBac vector, express-
ing TAF8 and TAF10 together, described in (7), and the cDNA was
inserted in the pVL1393 baculovirus expression vector digested
with Bam HI and Eco RI together with a primer coding for a FLAG-
tag on the 50 end of the hTAF8 cDNA. The mutated TAF8 (FLAG-
TAF8 MUT) was generated by site-directed mutagenesis using
pVL1393-FLAG-TAF8 WT vector as a template to delete the G
Figure 7. Schematic representation of the TFIID composition within WT, Taf8 KO and patient cells. In WT cells holo-TFIID, containing TBP and 13 TAFs, including WT
TAF8, is abundant in cells and drives faithful transcription. In Taf8 knockout cells, such as the mESCs described in Figure 4 of this study, loss of TAF8 results in im-
paired TFIID and no transcription. In contrast, in the patient fibroblasts either only partial TAF assemblies form, or the tiny (undetectable) amount of mutant TAF8 pro-
tein integrates into a TFIID-like complex. Either, or both of these complexes could mediate Pol II transcription initiation in patinet fibroblasts.
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residue at the border of exon 7 and 8 (see Fig. 1D). The WT FLAG-
TAF8 and the mutated FLAG-TAF8 cassettes encoding the P2A
self-cleaving peptide [GSGATNFSLLKQAGDVEENPGP (31,32)] and
the FLAG-GFP sequences were inserted the pVL1393 baculovirus
expression vector driven by the polyhedrin promoter. The con-
structs were verified by sequencing.
Isolation and culturing of human fibroblasts and
Drosophila S2 cells
A biopsy was taken from the patient which was used to estab-
lish a fibroblast cell line. Control fibroblasts were either HFF1
fibroblasts (ATCC) or control FD137 (male 3 years old).
Fibroblasts were cultured on 15 cm2 plates in standard fibroblast
medium (DMEM/F12 with GLUTAMAX, 10% fetal calf serum
(FCS), 15 mM HEPES and pen/strep) at 37C. Drosophila S2 cells,
used for ChIP spike-in were cultured in standard medium
(Schneider, 10% heat inactivated FCS and 0.5% pen/strep) at
28C with no CO2.
Generation of conditional Taf8mutant mice and
isolation of mESCs
A targeting construct was produced using a 17.6-kb fragment
from a C57BL/6-derived BAC (RP23–182C6) containing the entire
Taf8 gene. A loxP site was introduced 2.5 kb 50 of exon 1 and a
neomycin phosphotransferase expression cassette flanked by
FRT sites also containing a single loxP site at the 30 end was in-
troduced between exons 8 and 9 using the recombineering
method (43). This construct was electroporated into C57BL/6
ESCs, and correctly targeted cell lines were confirmed by
Southern blot analysis. PCR genotyping using three oligonucleo-
tides allowed the identification of the Taf8 exons 1 to 8-deleted
allele (Taf8–), the undeleted allele (Taf8lox) and the WT allele
(Taf8þ) simultaneously. Amplification of the WT and undeleted
alleles using primers (see Supplementary Material, Table S1)
resulted in products of 222 and 345 bps, respectively.
Amplification of the deleted allele resulted in a product of
429 bps.
Mice carrying the Taf8lox allele were bred to mice carrying
the Rosa26Cre-ERT2 allele (44) to produce Taf8lox/lox; Rosa26-
CreERT2 mice. mESCs were isolated from E3.5 blastocysts of
Taf8lox/loxTaf8lox/lox; Rosa26-CreERT2 matings, essentially as de-
scribed previously (45) with the modification that 2i medium
(46) and no feeder cells were used. Mouse ESCs were cultured in
medium containing two inhibitors (2i; CHIR99021 and
PD0325901, Axon MedChem), leukemia inhibitory factor, and 1%
FCS, on gelatin-coated plates. To induce deletion of Taf8, cells
were treated with 0.5 mM 4-OH tamoxifen (Sigma). Cell death
was measured by trypan blue exclusion.
WCE preparations
Two methods were used for WCE isolation. In the first method
(used for generating the WCE used in the co-IPs, and in the first
lane of Fig. 2B), pelleted cells were resuspended in 1 volume of
buffer containing 400 mM KCl, 20 mM Tris–HCl pH 7.5, 2 mM
dithiothreitol (DTT), 20% glycerol and 1 complete protease
inhibitors. The cells were frozen and thawed in liquid N2 four
times before being centrifuged at 13 000 RPM for 10 min to pellet
debris and isolate WCE supernatant. In the second method, pel-
leted cells were first resuspended in 1 volume of 600 mM KCl,
50 mM Tris–HCl pH 7.9, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT,
5 mM MgCl2, 0.5% Nonidet P-40 and 1 complete protease inhib-
itors, then incubated on ice for 10 min, then 3 volume of an-
other buffer containing 25 mM Tris–HCl pH 7.9, 5% glycerol,
0.5 mM DTT, 5 mM MgCl2, 0.1% Nonidet P-40, and 1 protease
inhibitor cocktail was added and incubated on ice for a further
10 min, followed by centrifugation at 13 000 RPM for 10 min to
pellet debris and isolate WCE supernatant.
Recombinant protein production
Recombinant baculoviruses were generated as described (47)
and used for protein complex production in Sf9 insect cell cul-
ture. Infected insect cells were harvested 48 h after cell infection
by centrifugation and stored at –80C until further use.
Pellets of baculovirus-infected Sf9 insect cells expressing
TAF8 constructs were resuspended in lysis buffer (400 mM KCl,
50 mM Tris–HCl pH 7.9, 10% glycerol, 0.2 mM EDTA, 0.5 mM DTT,
containing 1 protease inhibitor cocktail) and crude extracts
were prepared by three round freeze thawing cleared by
centrifugation.
Coimmunoprecipitation experiments
Confluent plates of TAF8 mutant and control fibroblasts were
harvested and lysed in WCE buffer no.1 (described earlier), and
3 mg of WCE from each genotype was used for each coimmuno-
precipitation. Protein G or A magnetic Dynabeads (Invitrogen
10002D or 10004D) were incubated with 6 ll of anti-TAF10 anti-
body (1H8), anti-TAF7 antibody (3475) or anti-GST
antibody (15TF21D10) for 2 h, then unbound antibody was re-
moved with two washes in IP100 buffer (25 mM Tris–HCl pH 7.5,
5 mM MgCl2, 10% glycerol, 0.1% Nonidet P-40, 100 mM KCl, 2 mM
DTT and 1 complete protease inhibitors). Fibroblast WCE was
made up to 600 ll in IP100 buffer, precleared then added to
Dynabeads coupled to antibody, and incubated overnight at 4C
with gentle agitation. The following day the magnetic beads
were isolated with a magnetic rack, the unbound material was
collected, and the beads were subjected to two rounds of wash-
ing for 10 min each with IP500 buffer (25 mM Tris–HCl pH 7.5,
5 mM MgCl2, 10% glycerol, 0.1% Nonidet P-40, 500 mM KCl, 2 mM
DTT and 1 complete protease inhibitors), followed by IP100
buffer. For the anti-TAF10 coimmunopurification, proteins
bound to the beads were eluted by adding 60 ll of 2 mg/ml com-
peting TAF10 peptide for 4 h, then again for 2 h (48). For the anti-
TAF7 co-IP, proteins were eluted with 0.1 M pH 2.8 glycine, then
neutralized with 2 M Tris pH 8.8. Co-IP-ed proteins were sepa-
rated on an 4–12% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel, along with the input extract and
flow through samples, and were probed with antibodies against
TFIID subunits.
Antibodies
Mouse monoclonal (mAb) and rabbit polyclonal (pAb) antibodies
raised against the following proteins have been described previ-
ously, or were purchased commercially: anti-TBP (mAb 3G3)
(49), anti-TAF2 (pAb 3083) (7), anti-TAF4 (mAb 32TA2B9) (11),
anti-TAF5 (mAb 1TA1C2) (50), anti-TAF6 (mAb 25TA2G7) (50),
anti-TAF7 (mAb 19TA) (51) and (pAb 3475) (52), anti-TAF8 (pAb
3478 and 3477) (52), anti-TAF10 (mAb 6TA2B11) (48) and TAF12
(22TA) (53), anti-GST antibody (mAb 15TF21D10) (54), anti-GFP
(Abcam Ab290), anti-c-Tubulin (Sigma Aldrich T6557), and anti-
FLAG (Sigma Aldrich M2).
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Mass spectrometry
IP-ed protein samples were analyzed using an Ultimate 3000
nano-RSLC (Thermo Scientific, San Jose, California) coupled in
line with a linear trap Quadrupole (LTQ)-Orbitrap ELITE mass
spectrometer via a nano-electrospray ionization source
(Thermo Scientific). Data were analyzed by calculation of the
NSAFbait (52,55). The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository (56,57) with the dataset identifier
PXD008084.
ChIP-seq and ChIP-qPCR
For each ChIP experiment, a minimum of 20 15 cm2 plates
were used per genotype. Approximately 2 106 fibroblast cells
were seeded onto each 15 cm2 plate, then the following day the
fibroblasts were fixed in 1% PFA for 10 min at room tempera-
ture, then the PFA was quenched with glycine at a final concen-
tration of 125 mM for 5 min at room temperature. After two
washes in cold 1 PBS, fibroblasts were scraped, and pelleted.
Nuclei were isolated by incubating cells with nuclear isolation
buffer (50 mM Tris–HCl pH 8.0, 2 mM EDTA pH 8.0, 0.5% Nonidet
P-40, 10% glycerol and 1 protease inhibitors) for 10 min at 4C
with gentle agitation, followed by centrifugation at 13 000 RPM
to pellet the nuclei. Nuclei were resuspended in sonication
buffer (0.1% SDS, 10 mM EDTA, 50 mM Tris–HCl pH 8.0 and 1
protease inhibitors) then chromatin was sheared with the
Covaris E220 sonicator and chromatin concentration was mea-
sured with the Qubit 3.0 (ThermoFischer). A minimum of 50 mg
of chromatin was used for each IP, which was diluted in ChIP
dilution buffer (0.5% Nonidet P-40, 16.7 mM Tris–HCl pH 8.0,
1.2 mM EDTA, 167 mM NaCl and 1 protease inhibitor) and
each sample was spiked with 1/10 amount of Drosophila
sheared chromatin for normalization. Antibodies used for the
ChIP included anti-RPB1 CTD (1PB 7G5) (58), and mouse IgG
(Jackson Laboratories) which were incubated with the chroma-
tin overnight with gentle agitation at 4C. The following day,
magnetic beads were isolated and washed for 5 min at 4C,
once with low salt wash buffer (0.1% SDS, 0.5% Nonidet P-40,
2 mM EDTA, 150 mM NaCl, 20 mM and Tris–HCl pH 8.0), high
salt wash buffer (0.1% SDS, 0.5% Nonidet P-40, 2 mM EDTA,
500 mM NaCl, 20 mM and Tris–HCl pH 8.0), and LiCl wash buffer
(0.2 M LiCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM
EDTA, 10 mM Tris–HCl pH8.0), then twice with TE buffer, then
the beads were incubated in freshly prepared elution buffer (1%
SDS, 0.1 M NaHCO3) at 65C with shaking to elute complexes.
Crosslinks were reversed with by adding NaCl at a final concen-
tration of 0.2 M overnight as well as 50 lg/ml RNase A at 65C
and the following day the samples were treated with 20 mg
Protinase K, 26.6 of 1 M Tris–HCl pH 7.9, and 13.3 ml of 0.5 M
EDTA, and DNA was isolated with phenol chloroform. The pre-
cipitated DNA was used to generate libraries with the
Diagenode MicroPlex Library Preparation kit v2 for ChIP-seq
according to the manufacturer’s instructions, with read lengths
of 1 50 bp, then the samples were sequenced on Hiseq 4000,
reads were mapped to the human hg38 and Drosophila dm3 as-
semblies. Samples were normalized on the basis of Drosophila
spike-in as described in (59) then peak calling was performed
using the MACS2 software (60). Heatmaps and Metagene plots
were generated by the seqMINER software (61). The ChIP-seq
data were deposited on the Gene Expression Omnibus (GEO)
database with the accession number GSE106252. ChIP-qPCR
primers were designed to span a region directly under the RNA
Pol II peaks identified by the Pol II ChIP-seq, for randomly se-
lected genes including GAPDH, HSP90AB1, SPARC, RPL13a,
ADAMST1 and ID3 as well as a negative region at chromosome
9. Primer sequences are detailed in Supplementary Material,
Table S1. The clustering of the genes according their Pol II den-
sity in the –2 to þ2 kb regions relative to the TSS was carried
out by the seqMINER software (61). Pol II traveling ratio was cal-
culated as described in (37), except that the TSS tag density val-
ues in –100 to þ300 bp regions for each gene in clusters 1 and 2
were divided by the corresponding gene body tag density val-
ues in þ300 to 2 kb regions.
Newly synthesized mRNA analysis
Cells were harvested, and RNA was extracted followed by
DNase I treatment, according to the manufacturer’s instructions
(Macherey-Nagel). cDNA was generated with Super Script II
(Thermo Fischer Scientific) using random hexamer primers,
according to the manufacturer’s instructions. To measure geno-
mic DNA contamination in the cDNA preparations, cDNA syn-
thesis reactions were conducted without reverse transcriptase
enzyme (–RT). The CP values generated from RT-qPCR with the
–RT samples were always >35 cycles, indicating that genomic
DNA contamination contribution was negligible. RT-qPCR pri-
mers were designed to amplify intron-exon boundaries
(Supplementary Material, Table S1).
Accession numbers
The ChIP-seq data were deposited on the GEO database with the
accession number GSE106252. The mass spectrometry proteo-
mics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository (56,57) with the
dataset identifier PXD008084.
Supplementary Material
Supplementary Material is available at HMG online.
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